Presage Biosciences is an oncology company that is pioneering an entirely novel approach to evaluating patient response to drugs in clinical trials.
Presage’s patented CIVO™ technology delivers microdoses of multiple drugs to different regions of a tumor – while the tumor is still in the patient. Observing molecular and cellular responses to drugs and combinations in an authentic human tumor has the potential to provide a more detailed understanding of tumor biology, directly embodying a patient’s own immune system, tumor microenvironment, and genetic background. It is Presage’s mission to use this understanding to improve the way that new drugs are developed and targeted, with the goal of ultimately providing more effective treatments to patients with cancer.
Through research alliances, Presage collaborates with biopharmaceutical companies to discover new drug combinations and assess novel agents in the most important model of cancer — the human patient. Presage also employs CIVO internally to develop promising oncology therapies.